pharmaphorum17h
FDA fast-tracks Lilly/Boehringer’s Jardiance in chronic kidney disease
The new indication could unlock a sizeable new market for Jardiance (empagliflozin), which is already approved to control blood sugar in type ... keep pace with rival drugs in the SGLT2 inhibitor ...
Knowridge18h
Diabetes and obesity can damage the liver to the point of failure – but few people know their risk of developing liver disease
Metabolic dysfunction-associated steatotic liver disease, or MASLD, is an umbrella term describing conditions related to a ...
FDA OK's Ozempic to protect kidneys in type 2 diabetes patients
A popular diabetes drug just got a major new approval—and it could be a game-changer for millions of Americans at risk for ...
FDA approves Ozempic to reduce risk of kidney disease progression, cardiovascular death
The Food and Drug Administration approved Ozempic to be used to lessen the risk of kidney disease from getting worse, end-stage kidney disease and cardiovascular disease-caused death for patients with ...
FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients
Ozempic has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic ...
Hosted on MSN21h
Novo Nordisk secures FDA approval for Ozempic in diabetes with CKD
The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Ozempic (semaglutide) to reduce certain risks ...
Southwest Virginia Today3hOpinion
Democrats should start with drug prices | Froma Harrop
President Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals.